跳至主要内容
临床试验/CTRI/2018/02/012077
CTRI/2018/02/012077尚未招募4 期

Exploratory evaluation of the potential for long-term retention of Gadolinium (Gd) in the bones of patients who have received Gadolinium based Contrast Agents (GdCAs) according to their medical history

Ecron Acunova GmbH0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • 1.Patient must be at least 18 years of age (or older if required by local regulations)
  • 2.Patient scheduled for an orthopaedic surgical procedure provided that the required amount of trans-operatory collection of bone and skin as defined per-protocol in section 5.1.3 is feasible and all inclusion and no exclusion criteria are met.
  • 3.Patient is scheduled to have sufficient bone removed during the orthopaedic surgical procedure and sufficient non-scarred skin tissue from the edge of the surgical incision or amputated part to permit sample collection, in the investigatorâ??s medical opinion
  • 4.Patient agreed to have bone and skin samples collected at the time of the surgical procedure(s)
  • 5.Patientâ??s surgical procedure and subsequent remission will not be altered by study specific skin biopsies, in the investigatorâ??s medical opinion
  • 6.Patient is fully informed about the study and has signed the informed consent form

排除标准

  • 1.Patient has received different GdCAs.
  • 2.Patient has received intra-articular GdCA or per any other non-i.v. route.
  • 3.Patient has received or is scheduled to receive GdCA within 1 month prior to the date of the scheduled orthopaedic surgical and study sample collection procedures.
  • 4.Patient has received any investigational product or has participated in any other clinical trial within 30 days prior to enrolling in this study.
  • 5.Patient suspected of, or diagnosed with, tumour of the skeletal system i.e.tumour, metastatic bone, and bone marrow disease in the region from where the skin and bone will be harvested.
  • 6.Patient has diagnosed or suspected NSF at time of enrolment.
  • 7.Patient presents with scarring in the region(s) of the scheduled surgical procedure(s) or of the skin sampling location, to the extent that collection of an unscarred skin sample is not feasible.
  • 8.Patient has a close affiliation with the investigational site; e.g., a relative of the investigator, dependent person (e.g., employee or student of the investigational site).

研究者

发起方
Ecron Acunova GmbH

相似试验

进行中(未招募)
1 期
Study to evaluate the aftereffects of Gadolinium-containing MRI contrast agents by analysing bone and skin samples of patients who undergo hip or knee replacement surgery.Retention of gadolinium/traces of metals/minerals to be determined in bone/skin specimens and evaluation of signs of nephrogenic systemic fibrosis in skin.
EUCTR2012-001439-30-PLavitas Life Sciences GmbH350
进行中(未招募)
1 期
Study to evaluate the after effects of Gadolinium-containing MRI contrast agents by analysing bone and skin samples of patients who undergo a medically indicated orthopaedic surgery procedure.Retention of gadolinium/traces of metals/minerals to be determined in bone/skin specimens and evaluation of signs of nephrogenic systemic fibrosis in skin.
EUCTR2012-001439-30-DEavitas Life Sciences GmbH135
进行中(未招募)
1 期
Study to evaluate the aftereffects of Gadolinium-containing MRI contrast agents by analysing bone and skin samples of patients who undergo hip or knee replacement surgery.
EUCTR2012-001439-30-ESEcron Acunova GmbH350
暂停
不适用
Exploratory evaluation of the potential for long-term retention of Gadolinium in the bones of patients who have received Gadolinium based Contrast Agents according to their medical history.- MRI with Gadolinium Contrast Agent received (independent of indication) - Hip or knee surgery planned
JPRN-UMIN000011916Ecron Acunova GmbH350
进行中(未招募)
1 期
ong-Term Safety and Efficacy Evaluation of amlitelimab in adult participants with moderate to severe atopic dermatitis.
EUCTR2021-002344-73-DESanofi-aventis recherche & développement315